The role of multidisciplinary centers in the diagnosis and treatment of neuroendocrine tumors: the experience of the Russian Expert Center for the morphological diagnosis of neuroendocrine tumors of the digestive tract at the M.F. Vladimirsky Moscow Regional Research Clinical Institute (MONIKI)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Most neuroendocrine tumors (NETs) are slow-growing neoplasms, often occurring in people of working age or very young, who need long-term follow-up and treatment. A multidisciplinary approach is currently the optimal method for the diagnosis and management of patients with NETs. It is associated with improving the quality and timing of diagnosis, developing the most rational individual algorithm for treating patients, increasing their survival, reducing treatment costs by eliminating the use of ineffective drugs. The global medical community considers the creation of regional interdisciplinary expert centers (IDEC) to be the global trend and the “gold" standard for the provision of medical care for NETS. In April 2019, in the Russian Federation a project to create an IDEC for the treatment of NETs was launched, and 6 such centers have already been created. The experience of the work of first of them, created on the basis of the M.F. Vladimirsky Moscow Regional Research Clinical Institute (MONIKI), is presented. From September 2019 to May 2020, 56 tumors of various localization were tested there. The problems of determining the somatostatin receptor expression in NETs of various localization in terms of indications for the use of somatostatin analogues are discussed.

Full Text

Restricted Access

About the authors

L. E Gurevich

M.F. Vladimirsky Moscow Regional Research Clinical Institute (MONIKI)

Email: larisgur@mail.ru
Dr. Sci., Professor, Department of Pathology, Oncology Department 61/2, build. 13, Shchepkin str., Moscow 129110, Russian Federation

E. V Bondarenko

M.F. Vladimirsky Moscow Regional Research Clinical Institute (MONIKI)

Moscow, Russia

V. E Ashevskaya

M.F. Vladimirsky Moscow Regional Research Clinical Institute (MONIKI)

Moscow, Russia

D. N Fedorov

M.F. Vladimirsky Moscow Regional Research Clinical Institute (MONIKI)

Moscow, Russia

References

  1. Dasari A, Shen C., Haiperin D., et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-42. doi: 10.1001/jamaoncol.2017.0589.
  2. Yao J, Hasson M., Phan A., et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072. doi: 10.1200/JCO.2007.15.4377.
  3. Oberg K. Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol. 2005;17:386391. doi: 10.1097/01. cco.0000167739.56948.a9.
  4. Modlin I.M., Moss S.F., Chung D.C., et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-1289. doi: 10.1093/jnci/djn275.
  5. Centers of Excellence (CoE) URL: https://www. enets.org/coe.html Last access: 14.08.2019.
  6. Kvols L.K., Brendtro K.L. The North American Neuroendocrine Tumor Society (NANETS) guidelines: Mission, goals, and process. Pancreas. 2010;39:705-6. doi: 10.1097/MPA.0b013e3181eb7451.
  7. Singh S., Law C. Multidisciplinary Reference Centers: The Care of Neuroendocrine Tumors. J Oncology Practice. 2010;6(6):e11-e16. doi: 10.1200/JOP2010.000098.
  8. Townsend A., Price T, Yeend S., et al. Metastatic Carcinoid Tumor Changing Patterns of Care Over Two Decades. J Clin Gastroenterol. 2010;44(3):195-99. doi: 10.1097/MCG.0b013e3181a9f10a.
  9. Strosberg J., Gardner N., Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89:471-76. doi: 10.1159/000197899.
  10. Chan D.L., Singh S. Systemic Therapy for Neuroendocrine Neoplasms. Digestive Disease Interventions. 2019;03(01):063-070. doi: 10.1055/s-0038-1675757.
  11. Гуревич Л.Е., Корсакова Н.А., Воронкова И.А. и др. Иммуногистохимическое определение экспрессии рецепторов к соматостатину 1, 2А, 3 и 5 типа в нейроэндокринных опухолях различной локализации и степени злокачественности. Альманах клинической медицины. 2016;44(3):378-90.
  12. Volante M., Brizzi M.P, Faggiano Aeta l. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20(11):1172-182. doi: 10.1038/modpathol.3800954.
  13. Schmida H.A., Lambertinib C., van Vugta H.H., et al. Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1-5: Development and Immunohistochemical Application in Neuroendocrine Tumors. Neuroendocrinology 2012;95:232-47.
  14. Bertherat J., Tenenbaum F., Perlemoine K., et al. Somatostatin Receptos 2 and 5 A are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003;88(11):5353-60. doi: 10.1210/jc.2002-021895.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies